Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

Melt Pharmaceuticals has reported results from its Phase III trial of MELT-300 non-opioid sedation tablet for cataract ...

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

The consortium aims to attract global pharma and medical device companies for clinical trial research investment in Israel.

Research published by COTA found DLBCL patients who start treatment within two weeks of diagnosis face worse outcomes than ...